Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD
Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD
This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.
Inclusion Criteria:
Exclusion Criteria: